C1s Inhibitors
1 drugsAbout C1s
C1s is a serine protease within the C1 complex of the classical complement pathway, a key part of the innate immune system. It initiates the complement cascade, clearing pathogens and cellular debris.
C1s is a potential therapeutic target because dysregulation of the complement system is implicated in various diseases. However, there is currently no genetic evidence directly linking C1s to specific diseases.
There is one FDA-approved drug, ENJAYMO, targeting C1s, developed by RECORDATI RARE DISEASES, INC. ENJAYMO, a biologic (other) modality, was first approved in 2022 and is used in a therapeutic area classified as 'Other'.
Top C1s Drugs
The competitive landscape is highly concentrated, with only one company having an approved drug.
High market concentration suggests potential for new entrants, but also high barriers to entry.
C1s Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets C1s, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for novel small molecule or antibody therapeutics.
C1s Clinical Trials 2 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on C1s. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
C1s Drug Approval Timeline (2022 - 2022)
The first and most recent drug targeting C1s, ENJAYMO, was approved in 2022.
Recent approval suggests growing interest, but also early stage of market development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on C1s. A trial counts if an approved drug acting on C1s is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.